Statement 2: If individual susceptibility testing is not available, the first-line recommended treatment in areas of high (>15%) or unknown clarithromycin resistance is bismuth quadruple therapy (BQT). If this is not available, non-bismuth concomitant quadruple therapy may be considered.
Agreement 92%	Grade B1